The pharmaceutical industry delivered a Covid-19 vaccine with unprecedented speed. What comes next in Covid treatments and other medical breakthroughs? Where are investment opportunities? A Barron's Roundtable on healthcare investing with Mikael Dolsten, chief scientist at Pfizer; Louise A. Chen, senior analyst at Cantor Fitzgerald; and Charles D. Kennedy, M.D., CEO of Blue Ox Healthcare Partners.
Read MoreSera Prognostics, Inc., The Pregnancy Company™, focused on improving maternal and neonatal health through innovative precision biomarker approaches, together with leading health benefits company Anthem, Inc. and its HealthCore, Inc. subsidiary, an evidence generation company, have launched and started to enroll patients in a study to determine whether a test, along with clinical interventions, can lead to improved health for newborns and mothers.
Read MoreSera Prognostics’ partnership with Anthem shows Blue Ox playbook in action. Joining forces on a clinical study to improve neonatal outcomes, the partnership illustrates Blue Ox’s strategy of backing innovations that both lower healthcare costs and improve patient outcomes.
Read MoreCharles sat down with Dechert’s Robert Darwin to discuss how PE investments in life sciences and healthcare fared in 2020, and what’s in store for those sectors this year and in years to come.
Read MoreDr. Charles Kennedy, CEO of Blue Ox Healthcare Partners, discusses updates in treatments and vaccines for Covid-19.
Read MoreCharles discusses the lessons learned from the COVID pandemic as well as the impact it will have on the healthcare industry and the investment environment going forward.
Read MoreObalon Therapeutics, Inc. (Nasdaq: OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it has executed a consulting agreement with Blue Ox Healthcare Partners, LLC, to provide consulting services to Obalon, including helping Obalon to develop and implement an effective coverage and reimbursement-based go-to-market strategy.
Read MoreDr. Charles Kennedy, chief executive officer and managing partner at Blue Ox Healthcare Partners, discusses the impact of Covid-19 on deals in the health care space, and what investment opportunities the pandemic has presented in the industry. He speaks on "Bloomberg Markets."
Read MoreSera Prognostics, Inc. today announced the appointment of Thomas J. Garite, M.D. as Vice President of Clinical Sciences. Dr. Garite will work closely with Sera to advance clinical development programs that support the company’s growth from development into a commercial-stage company.
Read MoreEpic Sciences, Inc. today announced that it will present three abstracts at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program to be held from May 29 – June 2, 2020. Epic Sciences will present new data demonstrating the role of circulating tumor cells (CTCs) in cancer prognosis and treatment outcomes.
Read MoreSera Prognostics, Inc., The Pregnancy Company® announced the publication of positive data in a large, independent, contemporary prospective U.S. clinical cohort study, TREETOP (NCT02787213), in the American Journal of Obstetrics & Gynecology Maternal Fetal Medicine.
Read MoreSalt Lake City Utah –Sera Prognostics, Inc., The Pregnancy Company™, focused on improving maternal and neonatal health through innovative precision biomarker approaches, today announced the appointment of Jay M. Moyes as Chief Financial Officer. Mr. Moyes joins Sera Prognostics as it transitions from rigorous scientific and groundbreaking clinical stage company into a rapidly growing commercial organization.
Read MoreSera Prognostics, Inc., the leading health diagnostics company dedicated to improving the lives of women and babies through individualized prenatal care, will be presenting at the upcoming Cowen 2020 Health Care Conference at the Boston Marriott Copley Place in Boston on Tuesday, March 3rd, at 11:30 a.m. ET.
Read MoreEpic Sciences, Inc. announced today it will present two abstracts at the 2020 American Society of Clinical Oncology Genitourinary Cancers Symposium to be held in San Francisco, February 13 – 15, 2020. The abstracts feature two analyses of the PROPHECY trial cohort. One abstract evaluates the androgen-receptor splice variant 7 (AR-V7) in circulating tumor cells (CTCs) as a predictor of resistance to anti-androgen therapy. The second abstract reports new data on CTC-based biomarkers of chromosomal instability and small-cell neuroendocrine transformation and their association to resistance to anti-androgen therapy.
Read MoreSera Prognostics, Inc., the leading women’s precision pregnancy company, today announced two podium presentations to take place at the Society for Maternal-Fetal Medicine’s 40th Annual Pregnancy Meeting in Grapevine, Texas, near Dallas, on February 3-8, 2020.
Read MoreSera Prognostics, Inc., the leading health diagnostics company dedicated to improve the lives of women and babies through individualized prenatal care, today, announced that the Prevent PTB clinical study conducted by Intermountain Healthcare is being prepared for publication in a peer-reviewed scientific journal. This study is the first of its kind to measure the impact on maternal and neonatal health and healthcare costs when standard medical interventions are used to proactively treat mothers screened at high risk for prematurity by the PreTRM® Test. (ClinicalTrials.gov Identifier: NCT03530332)
Read MoreEpic Sciences, Inc. today announced the presentation of new data demonstrating the feasibility of using its proprietary technology for the detection and characterization of rare cells to guide the treatment of breast cancer. The data to be presented show the use of Epic Sciences’ liquid biopsy test to profile circulating tumor cells (CTCs) based on morphological features, protein marker expression and genomic alterations. Epic Sciences will present the data at the 2019 San Antonio Breast Cancer Symposium held on December 10 – 14, in San Antonio, Texas.
Read MoreSera Prognostics, Inc., (“Sera” or the “Company”), the leading health diagnostics company dedicated to improving the lives of women and babies through individualized prenatal care, today announced that a key scientific publication, “Effects of Selective Exclusion of Patients on Preterm Birth Test Performance,” authenticates Sera as the leading authority in using biomarkers to assess preterm birth risk. Sera’s comprehensive, best practice approach for building predictive screening tests has resulted in PreTRM®: the only clinically-validated, commercially available blood test to accurately assess a woman’s individualized risk of delivering her infant prematurely.
Read MoreSera Prognostics, Inc. (“Sera” or the “Company”), the leading health diagnostics company dedicated to improving the lives of women and babies through individualized prenatal care, today announced it has raised $36 million in Series D financing. Blue Ox Healthcare Partners (“Blue Ox”), an investment firm providing growth capital to healthcare companies targeting individuality and value-based care, led the investment round alongside two strategic healthcare companies.
Read More
